NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

Post-LOE

naproxen and esomeprazole magnesium

Dr. Reddy's Laboratories

ANDAORALTABLET, DELAYED RELEASE

Approved

Oct 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM (naproxen and esomeprazole magnesium) by Dr. Reddy's Laboratories is cyclooxygenase inhibitors [moa]. Approved for adolescent patients 12 years of age, older weighing at least 38 kg, requiring naproxen for symptomatic relief of arthritis and 3 more indications. First approved in 2022.

Drug data last refreshed 18h ago

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Indications (6)

adolescent patients 12 years of age older weighing at least 38 kg

Worked on NAPROXEN AND ESOMEPRAZOLE MAGNESIUM at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.